Literature DB >> 19802602

Ceramides: a new player in the inflammation-insulin resistance paradigm?

J M R Gill1, N Sattar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19802602     DOI： 10.1007/s00125-009-1546-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  14 in total

Review 1.  Novel biochemical risk factors for type 2 diabetes: pathogenic insights or prediction possibilities?

Authors:  N Sattar; S G Wannamethee; N G Forouhi
Journal:  Diabetologia       Date:  2008-04-08       Impact factor: 10.122

2.  Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease.

Authors:  V D F de Mello; M Lankinen; U Schwab; M Kolehmainen; S Lehto; T Seppänen-Laakso; M Oresic; L Pulkkinen; M Uusitupa; A T Erkkilä
Journal:  Diabetologia       Date:  2009-08-11       Impact factor: 10.122

Review 3.  Ceramides in insulin resistance and lipotoxicity.

Authors:  Scott A Summers
Journal:  Prog Lipid Res       Date:  2005-12-19       Impact factor: 16.195

4.  Key role for ceramides in mediating insulin resistance in human muscle cells.

Authors:  Laura Pickersgill; Gary J Litherland; Andrew S Greenberg; Mark Walker; Stephen J Yeaman
Journal:  J Biol Chem       Date:  2007-03-03       Impact factor: 5.157

5.  Human skeletal muscle ceramide content is not a major factor in muscle insulin sensitivity.

Authors:  M Skovbro; M Baranowski; C Skov-Jensen; A Flint; F Dela; J Gorski; J W Helge
Journal:  Diabetologia       Date:  2008-05-06       Impact factor: 10.122

6.  Relationship between insulin sensitivity and sphingomyelin signaling pathway in human skeletal muscle.

Authors:  Marek Straczkowski; Irina Kowalska; Agnieszka Nikolajuk; Stella Dzienis-Straczkowska; Ida Kinalska; Marcin Baranowski; Malgorzata Zendzian-Piotrowska; Zofia Brzezinska; Jan Gorski
Journal:  Diabetes       Date:  2004-05       Impact factor: 9.461

7.  The role of skeletal muscle sphingolipids in the development of insulin resistance.

Authors:  Marek Straczkowski; Irina Kowalska
Journal:  Rev Diabet Stud       Date:  2008-05-10

8.  Ceramide content is increased in skeletal muscle from obese insulin-resistant humans.

Authors:  John M Adams; Thongchai Pratipanawatr; Rachele Berria; Elaine Wang; Ralph A DeFronzo; M Cameron Sullards; Lawrence J Mandarino
Journal:  Diabetes       Date:  2004-01       Impact factor: 9.461

9.  Increased skeletal muscle ceramide level in men at risk of developing type 2 diabetes.

Authors:  M Straczkowski; I Kowalska; M Baranowski; A Nikolajuk; E Otziomek; P Zabielski; A Adamska; A Blachnio; J Gorski; M Gorska
Journal:  Diabetologia       Date:  2007-08-28       Impact factor: 10.122

10.  Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.

Authors:  Jacob M Haus; Sangeeta R Kashyap; Takhar Kasumov; Renliang Zhang; Karen R Kelly; Ralph A Defronzo; John P Kirwan
Journal:  Diabetes       Date:  2008-11-13       Impact factor: 9.461
View more
  14 in total

1.  Role of ceramides in nonalcoholic fatty liver disease.

Authors:  Mangesh Pagadala; Takhar Kasumov; Arthur J McCullough; Nizar N Zein; John P Kirwan
Journal:  Trends Endocrinol Metab       Date:  2012-05-17       Impact factor: 12.015

Review 2.  Mitochondrial function in ageing: coordination with signalling and transcriptional pathways.

Authors:  Fei Yin; Harsh Sancheti; Zhigang Liu; Enrique Cadenas
Journal:  J Physiol       Date:  2015-09-16       Impact factor: 5.182

3.  Lipid-induced insulin resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced ceramide biosynthesis in mice.

Authors:  William L Holland; Benjamin T Bikman; Li-Ping Wang; Guan Yuguang; Katherine M Sargent; Sarada Bulchand; Trina A Knotts; Guanghou Shui; Deborah J Clegg; Markus R Wenk; Michael J Pagliassotti; Philipp E Scherer; Scott A Summers
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  Sulphated galactosylceramide.

Authors:  K Buschard
Journal:  Diabetologia       Date:  2010-02-24       Impact factor: 10.122

5.  Plasma Leptin Reflects Progression of Neurofibrillary Pathology in Animal Model of Tauopathy.

Authors:  Martin Cente; Stefan Zorad; Tomas Smolek; Lubica Fialova; Natalia Paulenka Ivanovova; Katarina Krskova; Lucia Balazova; Rostislav Skrabana; Peter Filipcik
Journal:  Cell Mol Neurobiol       Date:  2020-09-30       Impact factor: 5.046

6.  You aren't IMMUNE to the ceramides that accumulate in cardiometabolic disease.

Authors:  Joseph V Varre; William L Holland; Scott A Summers
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2022-02-23       Impact factor: 5.228

7.  Ceramides and glucosylceramides are independent antagonists of insulin signaling.

Authors:  Jose A Chavez; M Mobin Siddique; Siew Tein Wang; Jianhong Ching; James A Shayman; Scott A Summers
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

8.  Palmitate and insulin synergistically induce IL-6 expression in human monocytes.

Authors:  Robert C Bunn; Gael E Cockrell; Yang Ou; Kathryn M Thrailkill; Charles K Lumpkin; John L Fowlkes
Journal:  Cardiovasc Diabetol       Date:  2010-11-05       Impact factor: 9.951

9.  Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies.

Authors:  Maeve A McArdle; Orla M Finucane; Ruth M Connaughton; Aoibheann M McMorrow; Helen M Roche
Journal:  Front Endocrinol (Lausanne)       Date:  2013-05-10       Impact factor: 5.555

10.  Sphingolipid metabolic pathway: an overview of major roles played in human diseases.

Authors:  Raghavendra Pralhada Rao; Nanditha Vaidyanathan; Mathiyazhagan Rengasamy; Anup Mammen Oommen; Neeti Somaiya; M R Jagannath
Journal:  J Lipids       Date:  2013-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.